Click the play button below for an interview with Michelle Fromholzer at InformexCompany ProfileFerro Pfanstiehl Laboratories, Inc. works closely with clients ranging from virtual pharmaceutical companies to the world's largest multinational pharmaceutical and biopharmaceutical producers as a fully integrated solution provider supplying clinical or fully developed commercial quantities of ICH Q7A-compliant high potency active pharmaceutical ingredients (HPAI) drug substances and high purity carbohydrate-based excipients to the pharma industry. Based in Waukegan, Illinois, Ferro Pfanstiehl manufactures commercial quantities of high purity low endotoxin (HPLE) carbohydrates, high potency or cytotoxic active pharmaceutical ingredients, pharmaceutical intermediates and carbohydrate building blocks under current ICH Q7A good manufacturing practices. It maintains more than 20 active U.S. and international Drug Master Files. Ferro Pfanstiehl's high potency API kilo and commercial scale suites are SafeBridge certified.Ferro Pfanstiehl is a wholly-owned subsidiary of Ferro Corporation (NYSE:FOE), a leading global producer of technology-based performance materials for manufacturers. Headquartered in Cleveland, Ohio, Ferro has operations in more than 20 countries, sells its products in more than 100 countries and reported sales of $2.2 billion in 2007.